Pramipexole

Drug Profile

Pramipexole

Alternative Names: BI-Sifrol; Daquiran; Mirapex; Mirapex ER; Mirapex LA; Mirapexin; Pexola; Pramipexole extended-release - Boehringer Ingelheim; Sifrol; Sirfrol ER; SND 919; SND 919Y

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiparkinsonians; Benzothiazoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • No development reported Myoclonus
  • Discontinued Fibromyalgia; Gilles de la Tourette's syndrome; Schizophrenia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myoclonus in USA (PO)
  • 11 Jan 2012 Boehringer Ingelheim completes a phase III trial in Parkinson's disease in China (NCT01191944)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top